Why the study?
Does benazepril improve blood pressure control, renal outcomes, and cardiovascular morbidity/mortality in patients with hypertension?
Does benazepril improve blood pressure control, renal outcomes, and cardiovascular morbidity/mortality in patients with hypertension?
Benazepril is an effective antihypertensive agent that offers additional renal and cardiovascular protective benefits, particularly when used in combination therapy.
Answers are grounded in this paper and cite their sources.
Benazepril may support hypertension management with renal and CV benefits; leaves open need for contemporary RCTs.
Benazepril is a nonsulfhydryl ACE inhibitor with favorable pharmacodynamic and pharmacokinetic properties, well-established antihypertensive effects and a good tolerability profile. Recent clinical studies have demonstrated that patients treated with benazepril alone or in combination with hydrochlorothiazide or amlodipine may achieve beneficial renal outcomes that extend beyond blood pressure control. Furthermore, the recent Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial showed decreased cardiovascular morbidity and mortality with benazepril when administered as a cotreatment. An additional novel therapeutic area for benazepril is atrial fibrillation. Differences between combination therapies have implications for which patients may be best suited to particular interventions, and further studies are required to fully ascertain this potential.
No takes yet. Share an insight, caveat, or question.
Barrios et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: